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pare the two strategies, each using a Tenofovir-based backbone treatment. Effec-
tiveness was measured by virologic response, defined as the percentage of patients
with  50 viral copies/ml, based on a systematic review of recently published
prospective trials. Costs were estimated according to Belgian tariffs. Only direct
costs were considered, and were expressed in Euros (€). The time-horizon was of 48
weeks. A probabilistic sensitivity analysis was conducted to evaluate the robust-
ness of the results. RESULTS: Two prospective phase III trials were selected for
efficacy evaluation: data for Darunavir were extracted from the ARTEMIS trial (Mills
et cols.), whereas data for Atazanavir were extracted from the CASTLE trial (Molina
et cols.). Both compared the respectives drugs to Lopinavir. Based on an indirect
comparison, the rate of virologic response after 48 weeks of follow up was 84% (95%
CI: 82-86%) for Darunavir and 78% (95% CI: 76-80%) for Atazanavir, while total costs
were 5868,84€ and 4821,60€, respectively. The ICER was 18.011,04€ for Darunavir.
Sensitivity analysis showed that ICER depends mainly on the uni costs of the drugs,
as well as on their efficacy. However, it is relatively independant from side effects
and deaths related to treatment. CONCLUSIONS: Our results show that Darunavir,
used as the third agent (protease inhibitor), compared to Atazanavir, may be more
cost-effective for the treatment of naïve HIV-infected patients, in Belgium.
PIN49
ECONOMIC EVALUATION OF 13-VALENT PNEUMOCOCCAL VACCINE IN HIGH
RISK ELDERLY POPULATION, FROM THE PUBLIC PAYER PERSPECTIVE IN BRAZIL
Cruz RB1, Fernandes RA1, Takemoto M1, Cukier FN1, Fujii RK2, Roberts CS3, Presa J4,
Jardim E4, Mould J3
1ANOVA - Knowledge Translation, Rio de Janeiro, RJ, Brazil, 2Pfizer, Inc., São Paulo, São Paulo,
Brazil, 3Pfizer, New York, NY, USA, 4Pfizer Parmaceutics Inc., São Paulo, São Paulo, Brazil
OBJECTIVES: Invasive pneumococcal disease (IPD) is a major public health chal-
lenge. The elderly is a high risk (HR) population to develop IPD and this risk is raised
in the presence of chronic illness. This study aims to perform cost-effectiveness
analysis of 13-valent pneumococcal conjugated vaccine (PCV13) in elderly HR, from
a public payer perspective in Brazil. METHODS: A Markov model was developed to
simulate IPD outcomes in elderly HR after vaccination with PCV13 versus PPSV23
and no vaccination, with regard to associated direct costs in a 10-year time horizon.
Effectiveness parameters are avoided cases of IPD, meningitis, pneumonia, and
bacteremia. Medical costs included hospital days, medical personnel time, outpa-
tient visits, diagnostic tests and medications. Clinical data and costs were ex-
tracted from literature, presented in 2011USD. RESULTS: For an 1,000,000 patients
cohort, PCV13 avoided [14,159;14,885] bacteremia, [1,119;1,327] meningitis,
[190,831;198,098] hospitalized pneumonia, [153,569;150,599] non-hospitalized
pneumonia, and [56,102;58,686] IPD deaths, versus [PPSV23;no vaccination] respec-
tively. Medical and vaccination costs for PCV13 versus PPSV23 and no vaccination
were 7,901,973.76 BRL, 8,823,681.28 USD, and 8,327,792.71 USD, respectively. PCV13
was the dominant alternative in this cost-effectiveness analysis. CONCLUSIONS:
From the public payer perspective in Brazil, PCV13 showed to be dominant com-
pared to PPSV23 and no vaccination in elderly high risk population.
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OBJECTIVES: Hepatitis C is a disease with significant economic burden to health
care systems. Two recently approved protease inhibitors –telaprevir (TVR) and
boceprevir (BOC)- are expected to change the current treatment algorithm, since
their addition to peginterferon and ribavirin (PR) is associated with significantly
improved clinical outcomes compared to PR alone. This analysis aims to evaluate
the cost-effectiveness of a triple regimen with telaprevir (TVRPR) compared to
one with boceprevir (BOCPR) from the Greek National Health Service perspective.
METHODS: A decision analytic model based on treatment pathways and efficacy
data from four phase III clinical trials (Advance, Sprint-2, Realize and Respond-2)
was used to assess the cost-effectiveness of TVRPR and BOCPR . Clinical out-
come was measured in terms of sustained virologic response (SVR) rates. Drug
costs were estimated based on available EU prices in March 2012. We estimated the
average cost per cured (SVR) patient and ICERs over treatment naïve and experi-
enced patients and over the overall HCV G1 population (with a ratio of 1 to 4).
Treatment stopping rules were not considered in this analysis. One way sensitivity
analysis was performed over the proportion of naïve patients. Resource allocation
implications were also considered under a hypothetical fixed budget scenario.
RESULTS: The average cost per cured patient in the overall HCV G1 population was
€46.635 for TVRPR and €56.146 for BOCPR. In treatment naïve patients it was
€38.868 for TVRPR and €42.983 for BOCPR, whereas in treatment experienced
patients it was €48.966 and €59.902 respectively. In terms of ICERs TVRPR was
associated with lower costs and higher SVR rates, with an ICER of - €10.403 per
cured patient gained in the overall patient population. Results were robust in sen-
sitivity analysis. CONCLUSIONS: TVRPR was projected to be cost-effective com-
pared to BOCPR, allowing for more patients to be cured under a hypothetical fixed
budget.
PIN51
HEALTH ECONOMIC EVALUATION OF THE VACCINATION AGAINST HERPES
ZOSTER AND POSTHERPETIC NEURALGIA IN GERMANY
Ultsch B1, Reinhold T2, Siedler A3, Krause G3, Wichmann O3
1Robert Koch Institute / Charité Berlin, Berlin, Germany, 2Charite University Medical Center
Berlin, Germany, Berlin, Germany, 3Robert Koch Institute, Berlin, Germany
OBJECTIVES: After infection, varicella-zoster-virus can reactivate as herpes zoster
(HZ), a painful skin rash most commonly among the elderly. A HZ-complication is
long-lasting pain after rash disappearance: postherpetic neuralgia (PHN). A vaccine
has been licensed in Europe to prevent HZ/PHN in individuals aged 50 years. To
support decision-making concerning a possible vaccination-recommendation in
Germany we performed a health economic evaluation.METHODS:We developed a
5-state Markov-model with age-specific transition probabilities. We compared a
vaccination-strategy to a scenario without vaccination targeting different popula-
tion-cohorts aged 50 in Germany (50-54, 55-59, etc.) to identify the most cost-
effective strategy. Besides the payer-perspective (PP), the societal-perspective (SP)
- covering in addition to direct also indirect costs - was considered. Country-spe-
cific demographic, epidemiological, and cost-of-illness input-data were utilized.
We assumed a vaccine price of 100 Euro/dose, lifelong duration of protection, and
20% vaccination-coverage. All monetary amounts were in Euro 2010. The cycle-
length was a quarter, and the model ended when individuals died. The discount-
rate was 3% for both, outcomes and costs. Outcomes were number of HZ- and
PHN-cases avoided. Results were presented as incremental cost-effectiveness ra-
tios (ICERs) and number-needed-to-vaccinate (NNV). Univariate deterministic sen-
sitivity-analyses (DSA) were performed. RESULTS: When targeting a cohort aged
50-54 years, preventing one HZ-case costs approximately 400€ from PP and approx-
imately 280€ from SP. In this age-cohort the NNV was 6. DSA showed that results
were most sensitive to target-age at vaccination, vaccine price, and discount rate.
When increasing the target-age to 85 year-olds, ICERs were 3,646€ (PP) and 3,634€
(SP) per adverted HZ-case, respectively, indicating a lower cost-effectiveness of
vaccination in this age-cohort; NNV increased to 37. When considering prevention
of PHN-cases ICERs became less favourable. CONCLUSIONS: Vaccination appears
as valuable prevention-option especially when targeting the 50-54-years age-co-
hort. However, target-age at vaccination, price, and duration of protection will be
key-factors in decision-making.
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OBJECTIVES: To study economic efficiency of three regimes for pharmacotherapy
of acute bronchitis. Apart from classic therapy the first and second regimes in-
cluded the usage of drugs of human recombinant interferon-a2b in the form of
suppositories. METHODS: Patients suffering from acute bronchitis were randomly
split into three groups comprising 50 people each. The first group got classic ther-
apy (mucolytics, vitamins, alkaline drinks, heat reduction drugs) and suppositories
of interferon-a2b (genferon) by 1 mln ME injected rectally twice a day for the period
of 5 days. The second group was cured with interferon (viferon) by 1 mln ME twice
a day for the period of 5 days. The third group got the classic therapy only. The
pharmacoeconomical analysis estimated the general treatment cost and minimi-
zation of expenses. RESULTS: The average period of overcoming acute bronchitis
took 9 days for the first two groups and 12 days for the third group. The average
period of temporary work disability lasted for 7 [6; 8] days for the first two groups
and 10 [9; 12] days for the third group. The general cost for the first group amounted
to € 168.9, 167.1 for the second group and € 230.4 for the third group. The minimi-
zation of expenses reached € 61.5 for the first group and € 63.3 for the second one in
comparison with the classic method. Considering minimal costs of drugs the min-
imization of expenses amounted to € 56.5 and € 61 respectively. Considering ex-
penses for antibacterial therapy the minimization of expenses when taking into
account the average costs of drugs reached € 62.1 and € 64.4 respectively.
CONCLUSIONS: As a result, the pharmacotherapy of acute bronchitis when using
interferon is more justified than the classic method of therapy.
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OBJECTIVES: To assess the cost-effectiveness of maternal triple-drug ART or infant
nevirapine to reduce HIV transmission during breastfeeding from HIV-infected
Malawian mothers, not meeting treatment guidelines for their own health. Strat-
egies were evaluated at two entry points into the health system: 1) time of delivery,
for mothers who have not accessed ART antenatally, and 2) antenatally.
METHODS: Cost-effectiveness was evaluated in terms of health care costs per HIV
transmission averted, life-years gained, quality adjusted life-years (QALYs) gained,
and disability adjusted life-years (DALYs) averted. The risks of HIV transmission
associated with the interventions were taken from the Kesho Bora and BAN stud-
ies. Antenatal regimens were 1) zidovudine (ZDV); 2) ZDV, lamivudine (3TC), lopi-
navir/ritonavir; and (3) no antenatal regimen. The postnatal regimens were 1) ma-
ternal antiretrovirals (ZDV, 3TC, lopinavir/ritonavir); 2) infant nevirapine (NVP);
and 3) no extended post-natal prophylaxis. Scenario analyses included: alternate
drug combinations and prices, and earlier antenatal initiation. RESULTS: For moth-
ers presenting at delivery, infant NVP during breastfeeding is likely to be consid-
ered cost-effective. Incremental cost-effectiveness ratios (ICERs) compared to stan-
dard of care are $264 per HIV transmission averted, $15 per life-year saved, $16 per
QALY and $15 per DALY averted. For mothers presenting antenatally, antenatal
ZDV plus infant NVP during breastfeeding appears cost-effective. ICERs compared
to ZDV plus standard of care are $667 per HIV transmission averted, $37 per life-
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